Evidence map›Paper›PMID 42303642›Full record

ArticleNature communications2026

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.

Alessandro Larcher, Alberto Traverso, Patrick Scuri, Umberto Capitanio, Giacomo Musso, Daniela Canibus, Simone Barbieri, Luca Caivano, Alan Zambello, Marco Denti and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alessandro Larcher *Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Alberto Traverso *S-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy. traverso.alberto@hsr.it.ORCID http://orcid.org/0000-0001-6183-4429
Patrick ScuriS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Umberto CapitanioDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Giacomo MussoDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Daniela CanibusDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Simone BarbieriS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Luca CaivanoS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Alan ZambelloS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Marco DentiS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0009-0009-8488-7991
Riccardo CampiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0001-5237-0888
Sergio SerniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Salvatore GranataDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Anna PalmisanoS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Davide VignaleS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.
Fracnesco MontorsiDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Antonio EspositoS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0002-1170-6266
Carlo TacchettiS-RACE (San-Raffaele Ai CEnter), Vita-Salute San Raffaele University, Milan, Italy.ORCID http://orcid.org/0000-0003-4602-000X
Andrea SaloniaDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0002-0595-7165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection is the standard treatment for nonmetastatic renal cell carcinoma, yet survival outcomes vary significantly among patients. Current prognostic models lack precision and cannot be applied preoperatively. Here we show the development and validation of a preoperative, interpretable machine learning model to estimate cancer-specific mortality. Using real-world clinical data from 2536 patients and an independent external validation cohort of 580 patients, we combine random survival forests with white-box models to ensure clinical transparency. Our survival tree model relies on exactly eight preoperative features, including tumor size, lymph node involvement, and performance status. We demonstrate that this model outperforms the established GRANT model, achieving a C-index of 0.88 and a Brier score of 0.02 on the external cohort, with notable accuracy in the first year postsurgery. Finally, we provide this tool as a web-based application to facilitate personalized, preoperative risk stratification.

Indexed as

Artificial IntelligenceCarcinoma, Renal CellKidney NeoplasmsAgedFemaleHumansMachine LearningMaleMiddle AgedPredictive Learning ModelsPrognosisRandom Forest

Identifiers

PMID42303642
PMCPMC13434749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.